Home | Sitemap | Search | Contact A- A A+
   
 
    Public Member Support us  
 

IBCSG 13-93 

AC x 4 followed by CMF x 3 with or without a chemotherapy-free interval, +/- tamoxifen for premenopausal patients with node positive breast cancer who are not suitable for endocrine therapy alone

DESIGN

Design Trial 13-93

Results & Publications


Publications

Study Chairs
Prof. Monica Castiglione - Bern, Switzerland
Dr. Marco Colleoni - Milano, Italy

Statistician
Shari Gelber

Trial Coordinator
Holly Shaw

Data Managers
Tara Scolese, Dawn Weinbaum

IBCSG Data Management Center/FSTRF
4033 Maple Road
Amherst, New York 14226 USA
Phone: +1 716 834 0900
Fax: +1 716 836 6097
Email: ibcsg10-15@fstrf.org

Date of Activation
May 1993

Date of Closure
August 1, 1999

Targeted Accrual
1225 patients

Final Accrual
1294 patients


Results Publications Results & Publications
Other Pathology


News

01.04.2014:
The next  IBCSG Annual Meeting will take place in Vienna, Austria on March 21st and 22nd, 2015.

27.03.2014:
A few impressions from our audits

14.03.2014:
New publications are available  

All News

 
  Print